Trinity Biotech Gains Approval for PreClara™ Preeclampsia Testing Service

Trinity Biotech ( (TRIB) ) just unveiled an announcement.

On August 14, 2025, Trinity Biotech announced that it received regulatory approval from the New York State Department of Health to begin offering its FDA-cleared PreClara™ preeclampsia testing service. This approval is a significant milestone in the company’s maternal health strategy, enhancing its position in the U.S. diagnostics market. The PreClara™ test provides crucial insights for managing hypertensive disorders in pregnancy, potentially reducing neonatal costs by over $10 million per 1,000 patients. This development also supports the future introduction of Trinity Biotech’s PrePsia™ technology for early pregnancy risk assessment.

Spark’s Take on TRIB Stock

According to Spark, TipRanks’ AI Analyst, TRIB is a Neutral.

The overall stock score is primarily influenced by the company’s weak financial performance, characterized by declining revenues, high debt levels, and negative equity. Technical analysis provides some positive signals with bullish momentum, but the overbought RSI suggests caution. Valuation metrics are unfavorable due to negative earnings and lack of dividends.

To see Spark’s full report on TRIB stock, click here.

More about Trinity Biotech

Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The company develops, acquires, manufactures, and markets diagnostic systems for the point-of-care and clinical laboratory segments, and has recently entered the wearable biosensor industry. Trinity Biotech’s products are used to detect infectious diseases and quantify Haemoglobin A1c and other chemistry parameters, with a presence in over 75 countries worldwide.

Average Trading Volume: 4,384,017

Technical Sentiment Signal: Buy

Current Market Cap: $34.48M

Find detailed analytics on TRIB stock on TipRanks’ Stock Analysis page.